文献速递眼底病与葡萄膜炎

IVAN试验中年龄相关性黄斑变性继发黄斑下出血的关联与结局

Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial.
PubMed 文献 · Am J Ophthalmol · 2021-10-06

该研究为IVAN随机对照试验的二次分析,纳入535例未治疗的新生血管性年龄相关性黄斑变性患眼,比较基线有无黄斑下出血(SMH)患者的人口学、视力和视网膜形态。结果显示基线SMH与年龄较大、视网膜内液存在及基线视力较差相关,但12个月时视力差异不再显著,且与视网膜下纤维化、萎缩性瘢痕或中心视网膜厚度无显著关联。

要点

  • 基线SMH患者年龄更大且更常见视网膜内液。
  • 基线SMH患者视力较无SMH者差约6个字母(95%CI 4-8)。
  • 12和24个月时SMH与视力差异无显著关联。

核心结论

  • 基线存在SMH与年龄较大、视网膜内液及基线视力较差相关。
  • 至第12个月时,基线有SMH者视力不再有显著差异。

研究设计与样本

  • IVAN随机对照试验的二次分析,收集英国23家医院数据。
  • 纳入535例未治疗的新生血管性年龄相关性黄斑变性患眼,随访至少12个月且影像质量合格。
  • 患眼随机分配接受每月或按需雷珠单抗、每月或按需贝伐珠单抗治疗。

主要发现

  • 第12个月和第24个月时视力差异减小且不显著。
  • 基线SMH与视网膜下纤维化、萎缩性瘢痕或中心视网膜厚度无显著关联。

临床怎么用

  • 基线SMH提示视力预后较差,但随治疗至12个月视力差异不再显著。
  • 基线SMH并非视网膜下纤维化、萎缩性瘢痕或中心视网膜厚度的显著关联因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare demographics, visual acuity (VA) and retinal morphology between those with, and without baseline submacular hemorrhage (SMH) for patients enrolled in the Inhibit VEGF in Age-related Choroidal Neovascularization trial (IVAN). DESIGN: Secondary analyses of a randomized, controlled trial of image and clinical data. METHODS: Setting; The IVAN trial collected data in 23 UK hospitals. Study population; IVAN study eyes (with untreated neovascular age-related macular degeneration at randomization) with at least 12 months of follow-up and adequate imaging. Intervention; Study eyes were randomly assigned between monthly ranibizumab, as-needed ranibizumab, monthly bevacizumab, or as-needed bevacizumab. Imaging at baseline was graded independently for the presence, type, position, and extent of SMH. Main outcome measures; The main outcome measures were VA (primary outcome), subretinal fibrosis, atrophic scarring, and retinal thickness outcomes at 12 and 24 months RESULTS: Of 605 IVAN trial participants, 535 were included in this analysis. Patients with SMH at baseline (286 [53%]) were older (P = .010) and affected eyes were more likely to have intraretinal fluid present (P = .038). The VA was significantly worse in those with baseline SMH at month 0 (P < .001; estimate of difference 6 letters; 95% CIs, 4-8 letters), but the difference decreased and was not significant at month 12 or 24. No significant association was found between baseline SMH and subretinal fibrosis, atrophic scarring, or central retinal thickness. CONCLUSIONS: The presence of SMH at baseline was associated with age, intraretinal fluid, and decreased baseline VA. By month 12, VA was no longer significantly different in those who presented with SMH at baseline.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mehta A, Steel DH, Muldrew A, et al. Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial. Am J Ophthalmol. 2021. PMID: 34626573. doi:10.1016/j.ajo.2021.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。